Vertex Pharmaceuticals (VRTX) Deferred Taxes (2011 - 2026)

Vertex Pharmaceuticals' Deferred Taxes history runs 16 years deep, the most recent figure standing at -$65.3 million for Q1 2026.

• In Q1 2026, Deferred Taxes rose 65.92% year-over-year to -$65.3 million; the TTM figure through Mar 2026 stood at -$384.5 million (down 0.63% YoY), while the FY2025 annual figure was -$510.8 million, down 46.44% from the prior year.
• Deferred Taxes was -$65.3 million for Q1 2026 at Vertex Pharmaceuticals, down from $30.5 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $148.1 million in Q4 2022 to a low of -$235.9 million in Q3 2025.
• Historically, Deferred Taxes has averaged -$102.2 million across 5 years, with a median of -$118.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Deferred Taxes jumped 453.46% in 2022, then sank 821.95% in 2023.
• A 5-year view of Deferred Taxes shows it stood at $148.1 million in 2022, then plunged by 188.45% to -$131.0 million in 2023, then jumped by 139.39% to $51.6 million in 2024, then slumped by 40.89% to $30.5 million in 2025, then slumped by 314.1% to -$65.3 million in 2026.
• The last three Deferred Taxes figures came in at -$65.3 million (Q1 2026), $30.5 million (Q4 2025), and -$235.9 million (Q3 2025), per Business Quant data.